EYEG stock traded down $0.22 during midday trading on Thursday, reaching $6.68. 874 shares of the company’s stock traded hands, compared to its average volume of 939,523. The company has a market cap of $24.74 million, a price-to-earnings ratio of -1.48 and a beta of 2.55. The firm’s fifty day moving average price is $5.38 and its 200-day moving average price is $2.31. Eyegate Pharmaceuticals has a 52 week low of $2.25 and a 52 week high of $9.50.
In other news, major shareholder Armistice Capital Master Fund bought 605,001 shares of Eyegate Pharmaceuticals stock in a transaction dated Monday, September 30th. The stock was purchased at an average price of $3.12 per share, for a total transaction of $1,887,603.12. Corporate insiders own 47.50% of the company’s stock.
Eyegate Pharmaceuticals Company Profile
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.
Further Reading: Market Timing
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.